Opportunity Information: Apply for CDC RFA PS14 1402
Apply for CDC RFA PS14 1402
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.977 Preventive Health ServicesSexually Transmitted Diseases Control Grants.
- This funding opportunity was created on Jul 8, 2013 and posted on Jun 14, 2013.
- Applicants must submit their applications by Sep 12, 2013 Application Deadline Date September 12, 2013, 1159 p.m. U.S. Eastern Standard Time, on www.grants.gov. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $551,500,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $7,276,076.00 in funding.
- The number of recipients for this funding is limited to 84 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- 1. Eligible Applicants For Parts A STD AAPPS and Part B GISP Eligible public health agencies include all 50 states Los Angeles, CA San Francisco, CA District of Columbia Chicago, IL Baltimore, MD New York City, NY Philadelphia, PA Commonwealth of Puerto Rico and the U.S. Virgin Islands or their Bona Fide Agents. A Bona Fide Agent is an agency/organization identified by the state or local government as eligible to submit an application under the state or local eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS) is a CDC cooperative agreement funding opportunity designed to strengthen and modernize STD prevention programs in eligible U.S. jurisdictions. The focus is on building capacity in public health agencies so they can better assess local STD burdens, assure access to quality prevention and clinical services, develop and support effective policies, and implement prevention strategies that align with CDC guidance. The project period is five years, and the program is structured around measurable improvements in how communities identify, treat, and prevent sexually transmitted diseases, especially chlamydia (CT), gonorrhea (GC), and syphilis.
The FOA lays out four primary outcomes expected by the end of the five-year period. First, jurisdictions are expected to increase community screening and treatment in line with CDC recommendations, which typically means expanding routine and targeted screening in settings where people at higher risk are reached and ensuring timely, guideline-concordant treatment. Second, awardees are expected to improve services for STD clients and their partners, including stronger linkage-to-care approaches. That generally points to better partner services, quicker notification and treatment of partners, and smoother referrals into clinical care and supportive services when needed. Third, programs are expected to reduce reinfection, which implies a stronger emphasis on follow-up, partner management, retesting when appropriate, and addressing practical barriers that lead to untreated partners or incomplete care. Fourth, the FOA calls for increased knowledge among both communities and providers about STD treatment and prevention, local epidemiology, and policies that work, reflecting an expectation that recipients will invest in education, clinical guidance dissemination, and policy development to improve prevention and care quality.
Beyond the near-term outcomes, the FOA frames longer-term public health goals that reflect CDC priorities for STD control. These include reducing the incidence of chlamydia, gonorrhea, and syphilis and preventing the serious health consequences associated with them. It also emphasizes integrating STD services into broader clinical care across the healthcare system, meaning STD prevention and treatment should not be limited to specialized clinics but should be embedded into routine healthcare workflows such as primary care, reproductive health, and other points of care. Another long-term goal is to increase access to STD services for populations most at risk, indicating a priority on equity and targeted strategies that reach groups disproportionately affected by STDs. Finally, the FOA highlights emerging threats, particularly antibiotic-resistant gonorrhea, other emerging STDs, and congenital syphilis, signaling that awardees should strengthen surveillance, response readiness, and prevention strategies that can adapt to changing epidemiology and resistance patterns.
Administratively, this opportunity is a discretionary CDC funding program using a cooperative agreement mechanism, which typically means CDC expects substantial programmatic involvement beyond standard grant oversight, often through technical assistance, collaboration on performance expectations, and alignment with national strategies. The activity category is health, and the CFDA listing is 93.977, Preventive Health Services: Sexually Transmitted Diseases Control Grants. The opportunity anticipated 84 awards with an estimated total funding amount of $551,500,000 across recipients. Individual award amounts ranged from an award floor of $169,653 to an award ceiling of $7,276,076. There was no cost sharing or matching requirement stated.
Eligibility is limited to specified public health agencies: all 50 states plus certain large local jurisdictions (Los Angeles, San Francisco, Chicago, Baltimore, New York City, Philadelphia), as well as the District of Columbia, the Commonwealth of Puerto Rico, and the U.S. Virgin Islands. The FOA also allows applications from bona fide agents, meaning an agency or organization formally designated by a state or local government to apply on its behalf, with a legal binding agreement required as documentation of that status. The funding opportunity number is CDC-RFA-PS14-1402. It was posted June 14, 2013, with an application deadline of September 12, 2013 at 11:59 p.m. Eastern Time via grants.gov, and it was archived October 12, 2013. For access issues related to the full announcement, the listed point of contact was CDCs Procurement and Grants Office, Technical Information Management Section (TIMS), at 770-488-2700.
FAQs: Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS)
What is the STD AAPPS funding opportunity?
STD AAPPS is a CDC cooperative agreement funding opportunity designed to strengthen and modernize STD prevention programs in eligible U.S. jurisdictions. It focuses on building capacity in public health agencies to better assess local STD burden, assure access to quality prevention and clinical services, develop and support effective policies, and implement CDC-aligned prevention strategies.
What is the official title of the opportunity?
Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS).
Who is the funding agency?
The Centers for Disease Control and Prevention (CDC).
What type of funding mechanism is used?
This opportunity uses a cooperative agreement mechanism, which generally means CDC expects substantial programmatic involvement beyond standard grant oversight (for example, through technical assistance, collaboration on performance expectations, and alignment with national strategies).
Is this a discretionary grant program?
Yes. It is described as a discretionary CDC funding program.
What is the activity category?
Health.
What is the CFDA number for this program?
93.977, Preventive Health Services: Sexually Transmitted Diseases Control Grants.
What is the funding opportunity number (FOA number)?
CDC-RFA-PS14-1402.
How long is the project period?
Five years.
Which STDs are specifically emphasized in the program description?
The FOA specifically highlights chlamydia (CT), gonorrhea (GC), and syphilis.
What are the four primary outcomes expected by the end of the five-year period?
The FOA describes four main outcomes:
- Increased community screening and treatment in line with CDC recommendations.
- Improved services for STD clients and their partners (including stronger linkage-to-care approaches).
- Reduced reinfection.
- Increased knowledge among communities and providers about STD treatment and prevention, local epidemiology, and effective policies.
What does "increase community screening and treatment" generally mean in this FOA?
It generally points to expanding routine and targeted screening in settings that reach people at higher risk and ensuring timely, guideline-concordant treatment.
What does the FOA mean by improving services for STD clients and their partners?
It generally indicates stronger linkage-to-care approaches, including better partner services, faster notification and treatment of partners, and smoother referrals into clinical care and supportive services when needed.
What types of efforts are implied by the goal of reducing reinfection?
The FOA implies a stronger emphasis on follow-up, partner management, retesting when appropriate, and addressing practical barriers that result in untreated partners or incomplete care.
What does the FOA expect related to increasing knowledge among communities and providers?
It reflects an expectation that recipients will invest in education, dissemination of clinical guidance, and policy development to improve prevention and care quality, including knowledge about treatment and prevention, local epidemiology, and policies that work.
What longer-term public health goals does the FOA describe?
The FOA frames longer-term goals that include reducing the incidence of chlamydia, gonorrhea, and syphilis and preventing serious health consequences associated with them.
Does the FOA mention integrating STD services into broader healthcare settings?
Yes. It emphasizes integrating STD services into broader clinical care across the healthcare system so that STD prevention and treatment are embedded into routine healthcare workflows (such as primary care and reproductive health), not limited to specialized clinics.
Is there a focus on access for populations most at risk?
Yes. The FOA highlights increasing access to STD services for populations most at risk, indicating a priority on equity and targeted strategies for groups disproportionately affected by STDs.
Does the FOA address emerging threats like antibiotic resistance?
Yes. It highlights emerging threats, including antibiotic-resistant gonorrhea, other emerging STDs, and congenital syphilis, signaling a need to strengthen surveillance, response readiness, and prevention strategies that can adapt to changing epidemiology and resistance patterns.
How many awards were anticipated?
84 awards were anticipated.
What was the estimated total funding amount across recipients?
$551,500,000 (estimated total across recipients).
What were the minimum and maximum individual award amounts?
The award floor was $169,653 and the award ceiling was $7,276,076.
Was cost sharing or matching required?
No cost sharing or matching requirement was stated.
Who was eligible to apply?
Eligibility was limited to specified public health agencies: all 50 states; certain large local jurisdictions (Los Angeles, San Francisco, Chicago, Baltimore, New York City, Philadelphia); the District of Columbia; the Commonwealth of Puerto Rico; and the U.S. Virgin Islands.
Can an organization apply on behalf of a state or local government?
Yes. The FOA allows applications from bona fide agents, meaning an agency or organization formally designated by a state or local government to apply on its behalf.
What documentation is required for a bona fide agent to apply?
A legal binding agreement is required as documentation of bona fide agent status.
When was the FOA posted and when was the application deadline?
The FOA was posted on June 14, 2013. The application deadline was September 12, 2013 at 11:59 p.m. Eastern Time.
How were applications submitted?
Applications were to be submitted via grants.gov.
Is this funding opportunity still open?
No. It was archived on October 12, 2013.
Who was listed as the point of contact for access issues related to the full announcement?
CDC's Procurement and Grants Office, Technical Information Management Section (TIMS), at 770-488-2700.
Browse more opportunities from the same category: Health
Next opportunity: Establishment of an Academic Partnership in Business Management and Environmental Sciences with Karakoram International University in Gilgit, Pakistan
Previous opportunity: Rapid Secondary Analysis to Optimize Care for Patients with Multiple Chronic Conditions (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS14 1402
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS14 1402) also looked into and applied for these:
| Funding Opportunity |
|---|
| Addressing Methodological Challenges in Research for Patients with Multiple Chronic Conditions (R21) Apply for RFA HS 14 002 Funding Number: RFA HS 14 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $180,000 |
| Viral Hepatitis, Early Identification and Linkage to Care for Persons with Chronic HBV and HCV Infections Apply for CDC RFA PS12 120901SUPP13 Funding Number: CDC RFA PS12 120901SUPP13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| The Disability and Rehabilitation Research and Training Program Rehabilitation Research and Training Centers RRTCs) Promoting Healthy Aging for Individuals with Long Term Physical Disabilities CFDA Number 84.133B 10 Apply for IVV R1230 OPP1 06162013 Funding Number: IVV R1230 OPP1 06162013 Agency: IVV Test Agency Category: Health Funding Amount: $1,000 |
| NIBIB Biomedical Technology Service Centers (P30) Apply for PAR 13 249 Funding Number: PAR 13 249 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| State Protection and Advocacy Traumatic Brain Injury Program (PATBI) Apply for HRSA 14 004 Funding Number: HRSA 14 004 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| PPHF 2013 Prevention Research Centers Health Promotion and Disease Prevention Research Centers financed in part by 2013 Prevention and Public Health Funds Apply for RFA DP 09 001PPHF13 Funding Number: RFA DP 09 001PPHF13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Global Partnerships for Cancer Prevention and Control Apply for CDC RFA DP13 1312 Funding Number: CDC RFA DP13 1312 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Mentored Career Development Award to Build Research Capacity in Global Mental Health (K01) Apply for RFA MH 14 120 Funding Number: RFA MH 14 120 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of the National Violent Death Reporting System (NVDRS) CDC RFA CE09 904 Apply for CDC RFA CE13 1312 Funding Number: CDC RFA CE13 1312 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $255,000 |
| NIMHD Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42) Apply for RFA MD 13 009 Funding Number: RFA MD 13 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Maintaining Collection of National Violent Death Reporting System (NVDRS) Data CDC RFA CE08 802 Apply for CDC RFA CE13 1311 Funding Number: CDC RFA CE13 1311 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $240,000 |
| Maintaining Collection of National Violent Death Reporting System (NVDRS) Data CDC RFA CE07 704 Apply for CDC RFA CE13 1310 Funding Number: CDC RFA CE13 1310 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $235,000 |
| Local Partners for Orphans and Vulnerable Children Project Apply for RFA 620 13 000004 Funding Number: RFA 620 13 000004 Agency: Nigeria USAID Abuja Category: Health Funding Amount: $32,500,000 |
| Drug Docking and Screening Data Resource (U01) Apply for RFA GM 14 010 Funding Number: RFA GM 14 010 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| HIV Care Grant Program Part B AIDS Drug Assistance Program (ADAP) Emergency Relief Awards Apply for HRSA 13 202 Funding Number: HRSA 13 202 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Tobacco Control Regulatory Research (R21) Apply for RFA OD 13 010 Funding Number: RFA OD 13 010 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Tobacco Control Regulatory Research (R01) Apply for RFA OD 13 011 Funding Number: RFA OD 13 011 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Tobacco Control Regulatory Research (R03) Apply for RFA OD 13 012 Funding Number: RFA OD 13 012 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Immunization Enhanced Surveillance for New Vaccine Preventable Disease financed in part by 2013 Prevention and Public Health Funds Apply for RFA IP 11 010PPHF13 Funding Number: RFA IP 11 010PPHF13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) Apply for PAR 13 250 Funding Number: PAR 13 250 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS14 1402", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.